HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

mosapride

structure given in first source; gastrokinetic agent free of dopamine D2 receptor antagonist properties

Also Known As:

4-amino-5-chloro-2-ethoxy-N-((4-(4-fluorobenzyl)-2-morpholinyl)methyl)benzamide; AS 4370; AS-4370; mosapride citrate; Benzamide, 4-amino-5-chloro-2-ethoxy-N-((4-((4-fluorophenyl)methyl)-2-morpholinyl)methyl)-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1)

Networked: 84 relevant articles (24 outcomes, 21 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Yoshida, Naoyuki: 3 articles (01/2013 - 12/2002)
2.	Park, H: 2 articles (05/2015 - 02/2008)
3.	Kinoshita, Yoshikazu: 2 articles (10/2013 - 06/2010)
4.	Adachi, Kyoichi: 2 articles (10/2013 - 06/2010)
5.	Lee, In Seok: 2 articles (04/2013 - 03/2004)
6.	Cho, Yu Kyung: 2 articles (04/2013 - 03/2004)
7.	Choi, Myung-Gyu: 2 articles (04/2013 - 03/2004)
8.	Kim, Sang Woo: 2 articles (04/2013 - 03/2004)
9.	Watanabe, S: 2 articles (08/2011 - 06/2005)
10.	Yang, Tzeng-Huey: 2 articles (02/2011 - 08/2010)

Related Diseases

1.	Gastroesophageal Reflux (GERD) 12/01/2011 - "In this study, mosapride (MOS) was formulated in an ODF preparation that can be used for treatment of patients who suffer from gastrointestinal disorders, especially difficulty in swallowing due to gastroesophageal reflux disease. " 06/01/2010 - "The aim of the present study was to determine whether mosapride, a prokinetic agent, stimulates esophageal functions, and prevents acidic and non-acidic gastroesophageal reflux. " 06/01/2010 - "Effects of mosapride on esophageal functions and gastroesophageal reflux." 08/01/2009 - "Mosapride, an agent used in chronic, long-term therapy of gastro-esophageal reflux disease (GERD) was regarded as mediating its efficacy through prokinetic properties. " 10/01/2003 - "The effect of mosapride on oesophageal motor function and acid reflux in patients with gastro-oesophageal reflux disease."
2.	Dyspepsia (Indigestion) 01/01/2008 - "However, in one randomized, double-blind trial in patients with mild to severe disease, the improvement in overall symptoms of functional dyspepsia did not differ significantly between mosapride or placebo treatment. " 02/01/2004 - "Mosapride was safe and effective in improving the symptoms and gastric empty of functional dyspepsia." 05/01/2002 - "To evaluate the efficacy of three dosage regimens of mosapride compared with placebo in the treatment of functional dyspepsia. " 01/01/2015 - "The aim of this study was to assess the therapeutic effect of mosapride in patients with functional dyspepsia (FD). " 05/01/2002 - "Dose finding study of mosapride in functional dyspepsia: a placebo-controlled, randomized study."
3.	Constipation 05/28/2012 - "Mosapride citrate may be an effective and safe adjunct to PEG-electrolyte solution that leads to improved quality of bowel preparation, especially in patients without severe constipation." 01/01/2010 - "Mosapride improved reflux and constipation evaluated by GSRS. " 06/01/2005 - "The present study showed for the first time that mosapride citrate augmented lower gastrointestinal tract motility, as shown in CTT and videomanometry, and thereby ameliorated constipation in parkinsonian patients without serious adverse effects." 06/01/2005 - "The objective of this study is to perform an open study of mosapride citrate's effects on constipation, a prominent lower gastrointestinal tract disorder in parkinsonian patients. " 08/01/2011 - "These findings suggest that mosapride may have the potential to treat IBS patients with constipation and/or functional constipation. "
4.	Hypersensitivity (Allergy) 06/01/2012 - "The aim of this study was to assess the effects of mosapride citrate on visceral pain in a rat visceral hypersensitivity model. " 02/01/2012 - "Furthermore, we showed that famotidine ameliorated both delayed gastric emptying and gastric hypersensitivity, whereas mosapride only improved delayed gastric emptying." 06/01/2012 - "The effects of 5-HT4 receptor agonist, mosapride citrate, on visceral hypersensitivity in a rat model." 06/01/2012 - "The intraperitoneal injection of mosapride citrate also resulted in a significant reduction in the VMRs to CRD in a zymosan-induced visceral hypersensitivity rat model (67 ± 9%, P < 0.05). " 06/01/2012 - "Intraperitoneal injection of mosapride citrate resulted in a significant reduction in the VMRs to CRD in an acetic acid-induced visceral hypersensitivity rat model (61 ± 9%, P < 0.05). "
5.	Nausea 10/01/2013 - "GERD symptoms were improved after treatment in both groups, and postprandial bloating and nausea were improved in PPI plus mosapride group. " 11/30/2001 - "In addition, mosapride, a member of the benzamide family, was effective in alleviating fluvoxamine-induced nausea. " 01/01/2013 - "Mosapride citrate, a selective agonist of the 5-hydroxytryptaine (5-HT)₄ receptor, is typically used to treat heartburn, nausea, and vomiting associated with chronic gastritis or to prepare for a barium enema X-ray examination. "

Related Drugs and Biologics

1.	Omeprazole (Esomeprazole)
2.	Famotidine (Pepcid)
3.	Serotonin 5-HT4 Receptor Agonists
4.	Proton Pump Inhibitors
5.	pantoprazole (Protonix)
6.	Serotonin 5-HT3 Receptor Antagonists
7.	benzamide
8.	Acetic Acid (Vinegar)
9.	Fluvoxamine (Luvox)
10.	Zymosan

Related Therapies and Procedures

1.	Aftercare (After-Treatment)
2.	Intraperitoneal Injections
3.	Gastrostomy
4.	Resuscitation
5.	Oral Administration